Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Johnson & Johnson : J&J's Janssen Seeks Europe OK For Subcutaneous Darzalex in Multiple Myeloma

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/19/2019 | 07:31am EDT

By Colin Kellaher

Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Friday said is seeking approval from the European Medicines Agency for subcutaneous use of Darzalex in patients with multiple myeloma.

Darzalex is currently only approved for intravenous use.

Janssen said subcutaneous Darzalex is co-formulated with Halozyme Therapeutics Enhanze drug-delivery technology.

Janssen last week filed for U.S. Food and Drug Administration approval for the subcutaneous formulation of Darzalex in multiple myeloma, a cancer that forms in a type of white blood cells called plasma cells and causes cancer cells to accumulate in the bone marrow.

Write to Colin Kellaher at colin.kellaher@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
HALOZYME THERAPEUTICS, INC. -1.26% 16.47 Delayed Quote.14.01%
JOHNSON & JOHNSON -1.25% 130.6 Delayed Quote.2.48%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
08/19JOHNSON & JOHNSON : Congo to use second vaccine to fight Ebola
AQ
08/16JOHNSON & JOHNSON INVESTIGATION UPDA : Kahn Swick & Foti, LLC Continues to Inves..
BU
08/16JOHNSON & JOHNSON : Ebola Crisis-The Vaccines Debate
AQ
08/15JOHNSON & JOHNSON : Janssen Announces European Commission Approval of Imbruvica ..
AQ
08/13JOHNSON & JOHNSON : J&J's Janssen Gets EC OK for Expanded Use of Imbruvica
DJ
08/12JOHNSON & JOHNSON : Thinking about trading options or stock in AbbVie, Bristol-M..
PR
08/12JOHNSON & JOHNSON : Janssen Announces U.S. FDA Accelerated Approval for SIRTURO ..
AQ
08/09JOHNSON & JOHNSON : Janssen Announces U.S. FDA Accelerated Approval for SIRTUROÒ..
PU
08/09Canada enacts drug price crackdown, in blow to pharmaceutical industry
RE
08/09WHAT IS THE KEY OUTCOMES ANALYSIS OF : Pfizer, Amgen, Novartis, Bayer, Johnson &..
AQ
More news
Financials (USD)
Sales 2019 81 594 M
EBIT 2019 25 389 M
Net income 2019 18 319 M
Debt 2019 6 547 M
Yield 2019 2,84%
P/E ratio 2019 19,7x
P/E ratio 2020 17,4x
EV / Sales2019 4,36x
EV / Sales2020 4,09x
Capitalization 349 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 148,50  $
Last Close Price 132,25  $
Spread / Highest target 27,8%
Spread / Average Target 12,3%
Spread / Lowest Target -6,24%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.48%349 030
ROCHE HOLDING LTD.12.24%239 457
MERCK AND COMPANY12.80%220 679
NOVARTIS17.81%205 341
PFIZER-20.62%194 582
AMGEN5.82%123 538